Plazinemdor

Pharmaceutical compound From Wikipedia, the free encyclopedia

Plazinemdor (INNTooltip International Nonproprietary Name; developmental code name CAD-9303) is an NMDA receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.[1][2] It is taken orally.[1][2] The drug is intended for treatment of the negative and cognitive symptoms of schizophrenia.[2][3] Plazinemdor was originated by Cadent Therapeutics and is or was under development by Novartis.[1][2] As of April 2023, no recent development has been reported for schizophrenia.[1][2]

Other namesCAD-9303; CAD9303
Routes of
administrationOral[1]
Drug classNMDA receptor positive allosteric modulator
ATC code
  • None
Quick facts Clinical data, Other names ...
Plazinemdor
Clinical data
Other namesCAD-9303; CAD9303
Routes of
administration		Oral[1]
Drug classNMDA receptor positive allosteric modulator
ATC code
  • None
Identifiers
  • 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-[2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl]pyrrolo[2,3-d]pyrimidin-4-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H19ClF2N4O2
Molar mass432.86 g·mol−1
3D model (JSmol)
  • CC1(CN(C1)C(=O)CN2C=NC3=C(C2=O)C(=CN3C4CC4)C5=CC(=C(C=C5)F)Cl)F
  • InChI=1S/C21H19ClF2N4O2/c1-21(24)9-27(10-21)17(29)8-26-11-25-19-18(20(26)30)14(7-28(19)13-3-4-13)12-2-5-16(23)15(22)6-12/h2,5-7,11,13H,3-4,8-10H2,1H3
  • Key:NULHGWQIRTXKAY-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI